期刊文献+

昆明市三个地区主要癌症早死所致生命损失年分析 被引量:2

Years of Life Lost due to Common Cancers Among Three Areas of Kunming,Yunnan Province
原文传递
导出
摘要 [目的]分析昆明市某城区、郊区和农村2006年常见癌症早死所致疾病负担情况。[方法]以早死所致生命损失年(years of life lost,YLL)作为疾病负担的测量指标,采用3%的贴现率但不采用年龄权重按癌症死因和地区计算标化每千人口YLL率。[结果]昆明市郊区癌症的标化YLL率最高,其次为城区和农村。肺癌、肝癌、结直肠癌和胃癌的标化YLL率在昆明市三个地区中均排名前5位,且男性恶性肿瘤早死所致疾病负担均明显高于女性。除上述恶性肿瘤外,胰腺癌的标化YLL率在昆明市三个地区的男性中排名前5位;白血病的标化YLL率在昆明市农村女性中位居第2,而乳腺癌的标化YLL率在昆明市城区和郊区女性中排名前5位。[结论]肺癌、肝癌、结直肠癌、胃癌、乳腺癌和白血病是严重威胁昆明市三个地区居民健康的主要癌症,应作为预防和治疗的重点。
出处 《中国肿瘤》 CAS 2009年第5期366-368,共3页 China Cancer
基金 云南省自然科学基金资助项目(2007C217M)
  • 相关文献

参考文献11

二级参考文献75

共引文献425

同被引文献53

  • 1黄贵培,蔡琳,徐兴福.同安区居民癌症负担中早死所致生命损失分析[J].现代预防医学,2004,31(3):326-327. 被引量:1
  • 2孙建东,郭晓雷,李维卡,张吉玉,付振涛,鹿子龙,徐爱强,王涛,李卫.山东省恶性肿瘤疾病负担研究[J].中国卫生经济,2007,26(8):64-66. 被引量:41
  • 3Gravalos C,Jimeno A.HER2in gastric cancer:a new prognostic factor and a novel therapeutic target[J].Ann Oncol,2008,19(9):1 523.
  • 4Garnock-Jones KP,Keating GM,Scott LJ.Trastuzumab:a review of its use as adjuvant treatment in human epidermal growth factor receptor2(HER2)-positive early breast cancer[J].Drugs,2010,70(2):215.
  • 5Dai GH,Shi Y,Chen L,et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2over-expression[J].Hepatogastroenterology,2012,59(120):2 439.
  • 6Cortés-Funes H,Rivera F,Alés I,et al.PhaseⅡstudy of trastuzumab and cisplatin in patients with advanced gastric cancer(AGC)with HER2/neu overexpression/amplification[J].J Clin Oncol,2007,25(18):4 613.
  • 7Grávalos C,Gómez-Martín C,Rivera F,et al.PhaseⅡstudy of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer[J].Clin Transl Oncol,2011,13(3):179.
  • 8Qiu MZ,Li Q,Wang ZQ,et al.HER2-positive patients receiving trastuzumab treatment have acomparable prognosis with HER2-negative advanced gastric cancer patients:a prospective cohort observation[J].Int J Cancer,2014,134(10):2 468.
  • 9Egamberdiev DM,Djuraev MD,Tuydjanova K,et al.Our experience in the use of trastuzumab in patients with advanced stomach cancer[J].Ann Oncol,2010,21(Suppl8):839.
  • 10Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(To GA):a phase3,open-label,randomised controlled trial[J].Lancet,2010,376(9 742):687.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部